Genetic Determinants of Drug Resistance in Mycobacterium tuberculosis and Their Diagnostic Value

The development of molecular diagnostics that detect both the presence of Mycobacterium tuberculosis in clinical samples and drug resistance-conferring mutations promises to revolutionize patient care and interrupt transmission by ensuring early diagnosis. However, these tools require the identifica...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2016-09, Vol.194 (5), p.621-630
Main Authors: Farhat, Maha R, Sultana, Razvan, Iartchouk, Oleg, Bozeman, Sam, Galagan, James, Sisk, Peter, Stolte, Christian, Nebenzahl-Guimaraes, Hanna, Jacobson, Karen, Sloutsky, Alexander, Kaur, Devinder, Posey, James, Kreiswirth, Barry N, Kurepina, Natalia, Rigouts, Leen, Streicher, Elizabeth M, Victor, Tommie C, Warren, Robin M, van Soolingen, Dick, Murray, Megan
Format: Article
Language:English
Subjects:
Antitubercular Agents - pharmacology
Drug Resistance, Multiple, Bacterial - drug effects
Drug Resistance, Multiple, Bacterial - genetics
Genes, Bacterial - drug effects
Genes, Bacterial - genetics
Humans
Molecular Diagnostic Techniques
Mutation - drug effects
Mutation - genetics
Mycobacterium tuberculosis - drug effects
Mycobacterium tuberculosis - genetics
Mycobacterium tuberculosis - isolation & purification
Original
Sequence Analysis, DNA
Tuberculosis, Multidrug-Resistant - drug therapy
Tuberculosis, Multidrug-Resistant - genetics
Tuberculosis, Multidrug-Resistant - microbiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The development of molecular diagnostics that detect both the presence of Mycobacterium tuberculosis in clinical samples and drug resistance-conferring mutations promises to revolutionize patient care and interrupt transmission by ensuring early diagnosis. However, these tools require the identification of genetic determinants of resistance to the full range of antituberculosis drugs. To determine the optimal molecular approach needed, we sought to create a comprehensive catalog of resistance mutations and assess their sensitivity and specificity in diagnosing drug resistance. We developed and validated molecular inversion probes for DNA capture and deep sequencing of 28 drug-resistance loci in M. tuberculosis. We used the probes for targeted sequencing of a geographically diverse set of 1,397 clinical M. tuberculosis isolates with known drug resistance phenotypes. We identified a minimal set of mutations to predict resistance to first- and second-line antituberculosis drugs and validated our predictions in an independent dataset. We constructed and piloted a web-based database that provides public access to the sequence data and prediction tool. The predicted resistance to rifampicin and isoniazid exceeded 90% sensitivity and specificity but was lower for other drugs. The number of mutations needed to diagnose resistance is large, and for the 13 drugs studied it was 238 across 18 genetic loci. These data suggest that a comprehensive M. tuberculosis drug resistance diagnostic will need to allow for a high dimension of mutation detection. They also support the hypothesis that currently unknown genetic determinants, potentially discoverable by whole-genome sequencing, encode resistance to second-line tuberculosis drugs.
ISSN:1073-449X
1535-4970
DOI:10.1164/rccm.201510-2091OC